



IBA – ACQUISITION OF OWN SHARES COMPLETION OF THE SHARE BUYBACK PROGRAM

Immediate Release – May 27th, 2021

Louvain-la-Neuve, Belgium, May 27th, 2021 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on January 12th, 2021.

Under this program, IBA has requested a financial intermediary to repurchase up to 357.000 IBA ordinary shares on its behalf under the terms of a discretionary mandate agreement with validity until May 31st, 2021, effective as from January 13th, 2021, to cover the company’s obligations under a long term incentive plan for certain members of its personnel.

In the framework of this share buyback program, IBA repurchased 22.384 IBA shares on Euronext Brussels in the period from May 14th, 2021 up to and including May 20th, 2021, as follows:

Trade date	Shares purchased	Average price	Min price	Max price	Buyback amount
14-05-21	3.500	16,46 €	16,34 €	16,66 €	57.593,55 €
17-05-21	2.600	16,82 €	16,46 €	16,96 €	43.740,58 €
18-05-21	4.400	16,93 €	16,76 €	17,02 €	74.511,36 €
19-05-21	2.775	16,65 €	16,60 €	16,76 €	46.197,37 €
20-05-21	5.109	17,40 €	16,96 €	17,62 €	88.898,13 €
20-05-21	4.000	17,30 €	17,30 €	17,30 €	69.200,00 €
TOTAL	22.384	16,98 €	16,34 €	17,62 €	380.140,99 €

These transactions include the purchase of a block of 4.000 shares at a price of 17,30 EUR/share, which was executed on May 20th, 2021 at 10.01 AM on the central order book of Euronext Brussels (XBRU).

The total number of shares purchased under this program therefore amounts to the target of 357.000, which terminates the program, at an average price of 15,4576 EUR/share. As a result, IBA SA currently holds 831.221 treasury shares (directly and indirectly through its subsidiary IBA Investments SCRL), representing 2,76% of its share capital.

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

Press release

Inside / regulated information



IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at www.iba-worldwide.com

Contact person

IBA

Christian Matton,
Chief Legal Officer

shareholderrelations@iba-group.com